Muhammad M. Mohiuddin, MBBS

Education

1989 MBBS (MD), Medicine, Dow Medical College, Karachi, Pakistan

2023 DSc (Hon), Dow University of Health Sciences, Karachi, Pakistan

Postdoctoral Education and Training

1990-1991 Residency, Civil Hospital (Medicine & Surgery), Karachi, Pakistan

1991-1993 Fellowship, Transplantation Biology and Immunology, Department of Cardiothoracic Surgery Harrison Department of Surgical Research, University of Pennsylvania Medical Center, Philadelphia, PA

1993-1998 Fellowship, Transplantation Surgery, Department of Cardiothoracic Surgery, MCP-Hahnemann Medical School (Allegheny University), Philadelphia, PA

1997-1998 Fellowship, Bone marrow Transplantation, Institute for Cellular Therapeutics, Allegheny university of the Health Sciences, Philadelphia, PA

2003-2005 Fellowship, Human Islet Transplantation, University of Pennsylvania, Philadelphia, PA

Dr. Mohiuddin recently served as chief of transplantation section of Cardiothoracic Surgery Research Program and Senior Scientist at the National Heart Lung and Blood Institute of the National Institutes of Health. Before joining NIH in 2005 he held faculty positions at University of Pennsylvania, Philadelphia and Rush University, Chicago. Dr. Mohiuddin is involved in the field of xenotransplantation since 1992 and has been instrumental in starting the xenotransplantation research programs at the above institutions.

Dr. Mohiuddin received his MBBS (MD) degree from Dow Medical College in Karachi, Pakistan and after completing his surgical training at Civil Hospital Karachi moved to United States where he finished his first fellowship in Transplantation Biology at University of Pennsylvania (Verdi DiSesa) and later fellowship in bone marrow transplantation at Institute of Cellular Therapeutics (Suzanne Ildstad), MCP Hahnemann University (now Drexel University).

Dr. Mohiuddin’s primary interest is in understanding the role of B lymphocytes in Transplantation, especially xenograft rejection. His other interests include transplantation tolerance and immune modulation. He has made several contributions to the fields of transplantation and xenotransplantation with over 120 publications and over 100 abstracts as well as numerous presentations. His group holds the record of longest xenograft survival in a large animal model. The immunosuppressive regimen developed under his leadership is now used widely throughout the xenotransplantation field.

Dr. Mohiuddin is an elected councilor of International Xenotransplantation Association / TTS. He is a member of prestigious societies; The Transplantation Society and American Society of Transplant Physicians. He reviews manuscripts for journals; Transplantation, Transplant Immunology, xenotransplantation, Journal of Heart and Lung Transplantation, etc. He has received several NIH and non-NIH grants during his academic career. His recent work in cardiac xenotransplantation was highlighted widely in press throughout the world.

Cardiac xenotransplantation, immunosuppressive therapy, surgical procedures in large and small animal models, B cell immunology, immunomodulation, bone marrow transplantation

Mohiuddin MM, Singh AN, Scobie L, Goerlich C, et al. Graft dysfunction in compassionate use of genetically engineered pig-to-human cardiac xenotransplantation: a case report The Lancet DOI:10.1016/S0140-6736(23)00775-4 June 2023 

Griffith BP, Goerlich CE, Singh AK, Rothblatt M, Lau C, Shah A, Lorber M, Grazioli A, Saharia K, Hong S, Joseph S, Ayares D, Mohiuddin MM. Genetically Modified Pig-To-Human Cardiac Xenotransplantation. New England Journal of Medicine. June 2022

Goerlich C, Griffith BP, Shah A, Treffalls J, Zhang T, Mohiuddin MM, et al. A Standardized Approach to Orthotopic (Life-supporting) Porcine Cardiac Xenotransplantation in a Nonhuman Primate Model Transplantation DOI: 1097/TP.0000000000004508 January 2023

Singh AK, Goerlich C, Zhang T, Lewis BG, Hershfeld A, Mohiuddin MM. CD40-CD40L. Blockade: Update on Novel Investigational Therapeutics for Transplantation Transplantation DOI: 1097/TP.0000000000004469 December 2022

Mohiuddin MM, Goerlich CE, Singh AK, et al. Progressive Genetic Modifications of Porcine Cardiac Xenografts Extend Survival to 9 Months. Xenotransplantation; Wiley Online; March 2022

Mohiuddin MM, Singh A, Goerlich C. Preclinical rational and current pathways to support the first human clinical trials in cardiac xenotransplantation Human Immunology DOI:10.1016/j.humimm.2022.07.001 July 2022

Mohiuddin MM, Singh A, Goerlich C. Preclinical rational and current pathways to support the first human clinical trials in cardiac xenotransplantation Human Immunology DOI:10.1016/j.humimm.2022.07.001 July 2022

Mohiuddin MM, Singh AK, Corcoran PC, Thomas ML, Clark T, Lewis BG, Hoyt RF, Eckhaus M, Pierson RN, Belli AJ, Wolf E, Klymiuk N, Phelps C, Reimann KA, Ayares D, Horvath KA. Chimeric 2C10R4 anti-CD40 antibody therapy is critical for long-term survival of GTKO. hCD46. hTBM pig-to-primate cardiac xenograft. Nature Communications. 2016 Apr 5;7:a11138. doi: 10.1038/ncomms11138.

Mohiuddin MM, Singh AK, Corcoran PC, Hoyt RF, Thomas ML, Ayares D, Horvath KA. Genetically engineered pigs and target-specific immunomodulation provide significant graft survival and hope for clinical cardiac xenotransplantation. The Journal of Thoracic and Cardiovascular Surgery. 2014 Sep; 148(3): 1106-1114.

Porter CM, Horvath‐Arcidiacono JA, Singh AK, Horvath KA, Bloom ET, Mohiuddin MM. Characterization and expansion of baboon CD4+ CD25+ Treg cells for potential use in a non‐human primate xenotransplantation model. Xenotransplantation. 2007 Jul 28; 14(4): 298-308.

Mohiuddin MM, Ogawa H, Yin D, Shen J, Galili U. Antibody-mediated accommodation of heart grafts expressing an incompatible carbohydrate antigen. Transplantation. 2003 Feb 15; 75(3): 258-262.

Mohiuddin MM. Clinical xenotransplantation of organs: why aren't we there yet? PLOS Medicine 4(3): e75. 2007 Mar 27; PubMed PMID: 0040075.